Octreotide Acetate: Managing Growth-Release Hormones to Reduce Symptoms and Promote Balance

Octreotide Acetate: Managing Growth-Release Hormones to Reduce Symptoms and Promote Balance

Octreotide Acetate
Hormonal Agent

Octreotide AcetateOctreotide Acetate CAS #: 79517-01-04

Octreotide Acetate is prescribed for a variety of GI issues, mainly for severe diarrhea brought upon by carcinoid symptoms. Its designed to imitate the natural growth-hormone inhibitor in the body, which makes it easier for the endocrine system to do its job. This API limits the excess release of glucagon secretion and insulin, making it a prime candidate for treatment in a number of different disorders. First synthesized by a chemist in the late 1970s, researchers are still actively testing its capabilities every day. It may even be an eventual mainstream API for those suffering from obesity or certain types of infertility.

Taking Care of Symptoms

The most common uses of Octreotide Acetate is to reduce extreme watery diarrhea and flushing episodes brought about by traditional intestinal tumors. Patients use it to reduce noticeable redness in the face when the body is having a GI attack as well as to retain the body’s natural fluids and minerals. It’s used to suppress a number of different chemicals in the body, including serotonin, gastrin, and pancreatic polypeptide. Octreotide Acetate has been known to normalize growth hormone in those diagnosed with acromegaly brought about by adenomas. In fact, females with acromegaly and infertility may be able to take Octreotide Acetate to increase their chances of becoming pregnant. Octreotide Acetate is generally given either via self-injection or doctor-administrated injection.

How It Works

Octreotide Acetate is generally prescribed to those who aren’t good candidates for surgeries or other forms of treatment. It works by binding to the somatostatin receptors and inhibiting adenylyl cyclase, thereby encouraging a more balanced release of hormones. While it does not cure disorders, it can help reduce the severity so they body can overcome them naturally.  Common side effects include dizziness, bloating, constipation, and vomiting. Most people who use the API find their side effects are generally mild, though those with severe reactions should talk to their doctor or pharmacist.

Additional Precautions

Allergy symptoms for this API include trouble breathing, rash, or swelling of the face, though It’s unlikely that people will have this reaction. In truly extreme cases, Octreotide Acetate may potentially harm the liver, gallbladder, thyroid, blood, or even heart. Those with thyroid or gallbladder disorders, diabetes, or kidney stones may not be able to take this medication. Because the API works with natural growth hormones, it may stunt the growth of children who take it for longer than a year. Those who have carcinoid tumors may be able to decrease their likelihood of reoccurrence by changing their eating habits.

A Treatment for Obesity

Octreotide may be able to regulate a patient’s hormones so they can control their eating habits. When a person experiences any type of brain damage (e.g., trauma, side effects of radiation treatment, etc.) their hypothalamus may begin to malfunction. If the ventromedial hypothalamus is unable to tell the brain that it’s full, the person is likely to keep eating until they’re uncomfortable. This results in exhaustion and increased insulin release. In several small studies involving both overweight children and adults, researchers found that Octreotide was able to lower the BMI and weight of those taking the API as opposed to those taking the placebo. It also increased the patient’s level of physical activity and their overall quality of life.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in the distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities, expert regulatory support as well as other value-added services. Click to inquire about purchasing Octreotide Acetate CAS# 79517-01-04 API, or for more information such as DMF, cGMP, price, availability, samples, sourcing, purity and more.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service